Signaling pathways as therapeutic targets in biliary tract cancer

Jennifer Yang, Matthew R. Farren, Daniel Ahn, Tanios Bekaii-Saab, Gregory B. Lesinski

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: The incidence of biliary tract cancer (BTC) is increasing, and the disease is frequently diagnosed during advanced stages, leading to poor overall survival. Limited treatment options are currently available and novel therapeutic approaches are needed. A number of completed clinical trials have evaluated the role of chemotherapy for BTC, demonstrating a marginal benefit. Thus, there is increased interest in applying targeted therapies for this disease. Areas covered: This review article summarizes the role of chemotherapeutic regimens for the treatment of BTC, and highlights key signal transduction pathways of interest for targeted inhibition. Of particular interest are the MEK or MAP2K (mitogen-activated protein kinase kinase), phosphatidylinositol-3 kinase (PI3K) and signal transducer and activator of transcription-3 (STAT3) pathways. We discuss the available data on several promising inhibitors of these pathways, both in the pre-clinical and clinical settings. Expert opinion: Future treatment strategies should address targeting of MEK, PI3K and STAT3 for BTC, with a focus on combined therapeutic approaches.

Original languageEnglish (US)
Pages (from-to)485-498
Number of pages14
JournalExpert Opinion on Therapeutic Targets
Volume21
Issue number5
DOIs
StatePublished - May 4 2017

Fingerprint

Biliary Tract Neoplasms
Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinase
STAT3 Transcription Factor
Signal transduction
Chemotherapy
Therapeutics
Expert Testimony
Signal Transduction
Clinical Trials
Drug Therapy
Incidence

Keywords

  • Biliary tract cancer
  • cholangiocarcinoma
  • MEK
  • PI3K
  • STAT3
  • targeted therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Signaling pathways as therapeutic targets in biliary tract cancer. / Yang, Jennifer; Farren, Matthew R.; Ahn, Daniel; Bekaii-Saab, Tanios; Lesinski, Gregory B.

In: Expert Opinion on Therapeutic Targets, Vol. 21, No. 5, 04.05.2017, p. 485-498.

Research output: Contribution to journalReview article

Yang, Jennifer ; Farren, Matthew R. ; Ahn, Daniel ; Bekaii-Saab, Tanios ; Lesinski, Gregory B. / Signaling pathways as therapeutic targets in biliary tract cancer. In: Expert Opinion on Therapeutic Targets. 2017 ; Vol. 21, No. 5. pp. 485-498.
@article{992e562ac77a4d34a6a0809a3e8ba777,
title = "Signaling pathways as therapeutic targets in biliary tract cancer",
abstract = "Introduction: The incidence of biliary tract cancer (BTC) is increasing, and the disease is frequently diagnosed during advanced stages, leading to poor overall survival. Limited treatment options are currently available and novel therapeutic approaches are needed. A number of completed clinical trials have evaluated the role of chemotherapy for BTC, demonstrating a marginal benefit. Thus, there is increased interest in applying targeted therapies for this disease. Areas covered: This review article summarizes the role of chemotherapeutic regimens for the treatment of BTC, and highlights key signal transduction pathways of interest for targeted inhibition. Of particular interest are the MEK or MAP2K (mitogen-activated protein kinase kinase), phosphatidylinositol-3 kinase (PI3K) and signal transducer and activator of transcription-3 (STAT3) pathways. We discuss the available data on several promising inhibitors of these pathways, both in the pre-clinical and clinical settings. Expert opinion: Future treatment strategies should address targeting of MEK, PI3K and STAT3 for BTC, with a focus on combined therapeutic approaches.",
keywords = "Biliary tract cancer, cholangiocarcinoma, MEK, PI3K, STAT3, targeted therapy",
author = "Jennifer Yang and Farren, {Matthew R.} and Daniel Ahn and Tanios Bekaii-Saab and Lesinski, {Gregory B.}",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/14728222.2017.1306055",
language = "English (US)",
volume = "21",
pages = "485--498",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Signaling pathways as therapeutic targets in biliary tract cancer

AU - Yang, Jennifer

AU - Farren, Matthew R.

AU - Ahn, Daniel

AU - Bekaii-Saab, Tanios

AU - Lesinski, Gregory B.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: The incidence of biliary tract cancer (BTC) is increasing, and the disease is frequently diagnosed during advanced stages, leading to poor overall survival. Limited treatment options are currently available and novel therapeutic approaches are needed. A number of completed clinical trials have evaluated the role of chemotherapy for BTC, demonstrating a marginal benefit. Thus, there is increased interest in applying targeted therapies for this disease. Areas covered: This review article summarizes the role of chemotherapeutic regimens for the treatment of BTC, and highlights key signal transduction pathways of interest for targeted inhibition. Of particular interest are the MEK or MAP2K (mitogen-activated protein kinase kinase), phosphatidylinositol-3 kinase (PI3K) and signal transducer and activator of transcription-3 (STAT3) pathways. We discuss the available data on several promising inhibitors of these pathways, both in the pre-clinical and clinical settings. Expert opinion: Future treatment strategies should address targeting of MEK, PI3K and STAT3 for BTC, with a focus on combined therapeutic approaches.

AB - Introduction: The incidence of biliary tract cancer (BTC) is increasing, and the disease is frequently diagnosed during advanced stages, leading to poor overall survival. Limited treatment options are currently available and novel therapeutic approaches are needed. A number of completed clinical trials have evaluated the role of chemotherapy for BTC, demonstrating a marginal benefit. Thus, there is increased interest in applying targeted therapies for this disease. Areas covered: This review article summarizes the role of chemotherapeutic regimens for the treatment of BTC, and highlights key signal transduction pathways of interest for targeted inhibition. Of particular interest are the MEK or MAP2K (mitogen-activated protein kinase kinase), phosphatidylinositol-3 kinase (PI3K) and signal transducer and activator of transcription-3 (STAT3) pathways. We discuss the available data on several promising inhibitors of these pathways, both in the pre-clinical and clinical settings. Expert opinion: Future treatment strategies should address targeting of MEK, PI3K and STAT3 for BTC, with a focus on combined therapeutic approaches.

KW - Biliary tract cancer

KW - cholangiocarcinoma

KW - MEK

KW - PI3K

KW - STAT3

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85017554400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017554400&partnerID=8YFLogxK

U2 - 10.1080/14728222.2017.1306055

DO - 10.1080/14728222.2017.1306055

M3 - Review article

VL - 21

SP - 485

EP - 498

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 5

ER -